Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01128894 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 841
- Enrollment target
NCT01128894 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 841 participants.
The verdict
NCT01128894, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 841 participants
- Enrollment target
Study Summary
This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.
Interventions
- DRUG liraglutide
- BIOLOGICAL albiglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 841 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01128894
The ClinicalTrials.gov registry entry for NCT01128894 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 841 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which liraglutide is the first listed.
NCT01128894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01128894 about?
NCT01128894 is a clinical study titled "A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.". This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.
What is the current status of trial NCT01128894?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 841 participants. The study started on 2010-05. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01128894?
The interventions under investigation include: liraglutide (DRUG), albiglutide (BIOLOGICAL).
Who is sponsoring clinical trial NCT01128894?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.